Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics (CLDX)
:CLDX
Total Valuation
Celldex has a market cap or net worth of $1.58B. The enterprise value is $729.97M.
Market Cap$1.58B
Enterprise Value$729.97M
Share Statistics
Celldex has 66,406,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,406,550
Owned by Insiders0.29%
Owned by Institutions0.32%
Financial Efficiency
Celldex’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.81%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-25.81%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee37.74K
Profits Per Employee-848.73K
Employee Count186
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Celldex is ―. Celldex’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value2.18
Price to FCF―
Price to Operating Cash Flow-8.91
PEG Ratio―
Income Statement
In the last 12 months, Celldex had revenue of 7.02M and earned -157.86M in profits. Earnings per share was -2.45.
Revenue7.02M
Gross Profit7.02M
Operating Income-195.08M
Pretax Income-157.86M
Net Income-157.86M
EBITDA-191.90M
Earnings Per Share (EPS)-2.45
Cash Flow
In the last 12 months, operating cash flow was -186.19M and capital expenditures -1.13M, giving a free cash flow of -187.06M billion.
Operating Cash Flow-186.19M
Free Cash Flow-187.06M
Free Cash Flow per Share-2.82
Dividends & Yields
Celldex pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change-24.65%
50-Day Moving Average21.77
200-Day Moving Average22.33
Relative Strength Index (RSI)63.59
Average Volume (3m)915.08K
Important Dates
Celldex upcoming earnings date is Nov 5, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Celldex as a current ratio of 18.91, with Debt / Equity ratio of 0.46%
Current Ratio18.91
Quick Ratio18.91
Debt to Market Cap<0.01
Net Debt to EBITDA0.13
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Celldex has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Celldex EV to EBITDA ratio is -8.35, with an EV/FCF ratio of -10.04.
EV to Sales228.31
EV to EBITDA-8.35
EV to Free Cash Flow-10.04
EV to Operating Cash Flow-10.16
Balance Sheet
Celldex has $630.34M in cash and marketable securities with $3.03M in debt, giving a net cash position of -$627.31M billion.
Cash & Marketable Securities$630.34M
Total Debt$3.03M
Net Cash-$627.31M
Net Cash Per Share-$9.45
Tangible Book Value Per Share$11.18
Margins
Gross margin is 85.86%, with operating margin of -2778.89%, and net profit margin of -2248.76%.
Gross Margin85.86%
Operating Margin-2778.89%
Pretax Margin-2248.76%
Net Profit Margin-2248.76%
EBITDA Margin-2733.63%
EBIT Margin-2778.89%
Analyst Forecast
The average price target for Celldex is $55.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$55.75
Price Target Upside123.09% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-30.25%
EPS Growth Forecast-9.70%